Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Pre-Tax Margin

Income before tax as a percentage of revenue.

Prothena Corporation plcNASDAQ: PRTA

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to 64.1%

Pre-tax margin was 64.1% in Q1 FY2026, up 2234.2 pp from a year earlier. On a trailing-twelve-month basis it was -182.9%, down 98.9 pp year over year. Over 3 fiscal years it narrowed by 1840.8 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
64.1%+102821.2 pp QoQ
Last fiscal yearDec 2025
-2073.8%-1978.4 pp YoY
LTMMar 2026
-182.9%-98.9 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2234.2 pp——
1 year-1978.4 pp——
3 years-1840.8 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-2073.8%
Year-over-year change
-1978.4pp

Pre-Tax Margin vs competitors

How PRTA compares with its peers on the latest reported figures

  • PRTA's LTM Mar 2026 pre-tax margin of -182.9% is the 2nd highest of the 4 companies compared; the peer median is -1788.8%.
  • Its year-over-year change of -98.9 pp is the 2nd highest of 3, against a peer median of -807.1 pp.
  • Over three fiscal years its change of -1840.8 pp compares with a peer median of -97.5 pp.
PRTA Competitors Peer median
Pre-Tax Margin for PRTA and competitors
Company Period LTM level YoY 3-year change
BIIBBiogen Inc.LTM Jun 20268.6% -9.4 pp-21.0 pp
PRTAProthena Corporation plcLTM Mar 2026-182.9% -98.9 pp-1840.8 pp
ACIUAC Immune S.A.LTM Mar 2026-1788.8% -1604.8 pp-173.9 pp
DNLIDenali Therapeutics Inc.LTM Jun 2026-14188.4% ——
ANNXAnnexon, Inc.FY2025— ——
AVXLAnavex Life Sciences Corp.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
PMNProMIS Neurosciences, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding PRTA) -1788.8%-807.1 pp-97.5 pp

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue200.58M53.91M91.37M135.16M9.68M
Cost of Revenue00003.7M
Gross Profit200.58M53.91M91.37M135.16M5.98M
Gross Margin100.0%100.0%100.0%100.0%61.8%
Research & Development82.28M135.56M220.57M222.52M134.85M
Selling, General & Admin46.32M49.9M61.84M67.2M59.39M
Operating Expenses128.6M185.46M282.41M289.72M190.54M
Depreciation & Amortization1.12M744K928K893K3.7M
EBITDA73.04M(124.86M)(159.55M)(128.04M)(197.13M)
EBITDA Margin36.4%-231.6%-174.6%-94.7%-2035.6%
Operating Income71.98M(131.56M)(191.04M)(154.56M)(184.56M)
Operating Margin35.9%-244.1%-209.1%-114.4%-1905.8%
Interest Income42K6.35M31.01M25.82M14.14M
Interest Expense00000
Other Income / Expenses(54K)5.95M30.56M25.63M(16.27M)
Income Before Tax71.92M(125.61M)(160.48M)(128.93M)(200.83M)
Pre-Tax Margin35.9%-233.0%-175.6%-95.4%-2073.8%
Income Tax Expense4.95M(8.66M)(13.45M)(6.62M)43.26M
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Net Margin33.4%-217.0%-160.9%-90.5%-2520.6%
EPS (Basic)1.51(2.47)(2.76)(2.27)(4.53)
EPS (Diluted)1.38(2.47)(2.76)(2.27)(4.53)
Weighted Avg Shares44.23M47.37M53.22M53.77M53.83M
Weighted Avg Shares (Diluted)48.46M47.37M53.22M53.77M53.83M

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.